These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Dehydrophenylalanine derivatives as VLA-4 integrin antagonists. Porter JR; Archibald SC; Brown JA; Childs K; Critchley D; Head JC; Parton TA; Robinson MK; Shock A; Taylor RJ; Warrellow GJ Bioorg Med Chem Lett; 2003 Mar; 13(5):805-8. PubMed ID: 12617895 [TBL] [Abstract][Full Text] [Related]
8. Substituted N-(3,5-dichlorobenzenesulfonyl)-L-prolyl-phenylalanine analogues as potent VLA-4 antagonists. Kopka IE; Young DN; Lin LS; Mumford RA; Magriotis PA; MacCoss M; Mills SG; Van Riper G; McCauley E; Egger LE; Kidambi U; Schmidt JA; Lyons K; Stearns R; Vincent S; Colletti A; Wang Z; Tong S; Wang J; Zheng S; Owens K; Levorse D; Hagmann WK Bioorg Med Chem Lett; 2002 Feb; 12(4):637-40. PubMed ID: 11844689 [TBL] [Abstract][Full Text] [Related]
9. N-(arylacetyl)-biphenylalanines as potent VLA-4 antagonists. Li B; de Laszlo SE; Kamenecka TM; Kopka IE; Durette PL; Lanza T; MacCoss M; Tong S; Mumford RA; McCauley ED; Van Riper G; Schmidt JA; Hagmann WK Bioorg Med Chem Lett; 2002 Aug; 12(16):2141-4. PubMed ID: 12127523 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of eosinophilia in vivo by a small molecule inhibitor of very late antigen (VLA)-4. Okigami H; Takeshita K; Tajimi M; Komura H; Albers M; Lehmann TE; Rölle T; Bacon KB Eur J Pharmacol; 2007 Mar; 559(2-3):202-9. PubMed ID: 17234179 [TBL] [Abstract][Full Text] [Related]
12. Discovery of N-{N-[(3-cyanobenzene) sulfonyl]-4(R)-(3,3-difluoropiperidin-1-yl)-(l)-prolyl}-4-[(3',5'-dichloro-isonicotinoyl) amino]-(l)-phenylalanine (MK-0617), a highly potent and orally active VLA-4 antagonist. Venkatraman S; Lebsack AD; Alves K; Gardner MF; James J; Lingham RB; Maniar S; Mumford RA; Si Q; Stock N; Treonze KM; Wang B; Zunic J; Munoz B Bioorg Med Chem Lett; 2009 Oct; 19(19):5803-6. PubMed ID: 19713111 [TBL] [Abstract][Full Text] [Related]
13. Quantitative structure activity relationship studies of piperazinyl phenylalanine derivatives as VLA-4/VCAM-1 inhibitors. Bhargava D; Karthikeyan C; Moorthy NS; Trivedi P Med Chem; 2009 Sep; 5(5):446-54. PubMed ID: 19534682 [TBL] [Abstract][Full Text] [Related]
14. Discovery of N-{N-[(3-cyanophenyl)sulfonyl]-4(R)-cyclobutylamino-(L)-prolyl}-4-[(3',5'-dichloroisonicotinoyl) amino]-(L)-phenylalanine (MK-0668), an extremely potent and orally active antagonist of very late antigen-4. Lin LS; Lanza T; Jewell JP; Liu P; Jones C; Kieczykowski GR; Treonze K; Si Q; Manior S; Koo G; Tong X; Wang J; Schuelke A; Pivnichny J; Wang R; Raab C; Vincent S; Davies P; Maccoss M; Mumford RA; Hagmann WK J Med Chem; 2009 Jun; 52(11):3449-52. PubMed ID: 19441819 [TBL] [Abstract][Full Text] [Related]
16. Discovery and evaluation of N-(triazin-1,3,5-yl) phenylalanine derivatives as VLA-4 integrin antagonists. Porter JR; Archibald SC; Brown JA; Childs K; Critchley D; Head JC; Hutchinson B; Parton TA; Robinson MK; Shock A; Warrellow GJ; Zomaya A Bioorg Med Chem Lett; 2002 Jun; 12(12):1591-4. PubMed ID: 12039569 [TBL] [Abstract][Full Text] [Related]
17. A small molecule alpha4beta1/alpha4beta7 antagonist differentiates between the low-affinity states of alpha4beta1 and alpha4beta7: characterization of divalent cation dependence. Egger LA; Cao J; McCallum C; Kidambi U; Van Riper G; McCauley E; Mumford RA; Lanza TJ; Lin LS; de Laszlo SE; Young DN; Yang G; Dean DC; Raab CE; Wallace MA; Jones AN; Hagmann WK; Schmidt JA; Pepinsky RB; Scott DM; Lee WC; Cornebise MA; Detmers PA J Pharmacol Exp Ther; 2003 Sep; 306(3):903-13. PubMed ID: 12766251 [TBL] [Abstract][Full Text] [Related]
18. N-(pyrimidin-4-yl) and N-(pyridin-2-yl) phenylalanine derivatives as VLA-4 integrin antagonists. Porter JR; Archibald SC; Brown JA; Childs K; Critchley D; Head JC; Hutchinson B; Parton TA; Robinson MK; Shock A; Warrellow GJ; Zomaya A Bioorg Med Chem Lett; 2002 Jun; 12(12):1595-8. PubMed ID: 12039570 [TBL] [Abstract][Full Text] [Related]
20. Critical period for a teratogenic VLA-4 antagonist: Developmental effects and comparison of embryo drug concentrations of teratogenic and non-teratogenic VLA-4 antagonists. Crofts F; Rohatagi S; Pino M; DeLise B; Zhang J; Nguyen M; Guittin P; Barbellion S; Brunel P; Hofmann T; Schmidt J; Wong M; Lockey P; Lerman S; Clark R Birth Defects Res B Dev Reprod Toxicol; 2004 Apr; 71(2):69-79. PubMed ID: 15098200 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]